Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 585,389,312
  • Shares Outstanding, K 2,408,613
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 30,550 M
  • EBITDA $ 38,053 M
  • 60-Month Beta 0.34
  • Price/Sales 6.24
  • Price/Cash Flow 17.29
  • Price/Book 7.21

Options Overview Details

View History
  • Implied Volatility 27.20% (+0.89%)
  • Historical Volatility 15.70%
  • IV Percentile 93%
  • IV Rank 65.03%
  • IV High 35.15% on 04/08/25
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 7) 5.15 (2.12%)
  • Put/Call Vol Ratio 0.65
  • Today's Volume 15,825
  • Volume Avg (30-Day) 17,095
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 367,806
  • Open Int (30-Day) 370,153
  • Expected Range 237.89 to 248.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $2.69
  • Number of Estimates 8
  • High Estimate $2.85
  • Low Estimate $2.41
  • Prior Year $2.77
  • Growth Rate Est. (year over year) -2.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
232.24 +4.65%
on 03/24/26
247.88 -1.95%
on 03/03/26
-5.52 (-2.22%)
since 03/02/26
3-Month
200.91 +20.97%
on 01/05/26
251.71 -3.44%
on 03/02/26
+35.69 (+17.21%)
since 01/02/26
52-Week
141.50 +71.76%
on 04/09/25
251.71 -3.44%
on 03/02/26
+87.68 (+56.44%)
since 04/02/25

Most Recent Stories

More News
This Dividend King Is Down 26%. When Will It Bounce Back?

Abbott Laboratories is down 26% from its 52-week high due to a soft quarter. With 54 consecutive years of dividend hikes and guidance calling for mid-single-digit organic sales growth plus 10% EPS expansion,...

ABT : 102.87 (+0.48%)
JNJ : 243.04 (-0.44%)
MDT : 86.63 (+0.66%)
$INX : 6,582.69 (+0.11%)
ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Johnson & Johnson presents new data showing high rates of complete skin clearance achieved at Week 24 and Week 52 in ICONIC-ADVANCE 1 and 2 studies

JNJ : 243.04 (-0.44%)
A Q2 2026 Playbook for Navigating Market Uncertainty

For investors looking to rebalance in Q2, here are three stocks that combine growth and defense to help investors stay invested during volatile markets

MSFT : 373.46 (+1.11%)
JNJ : 243.04 (-0.44%)
NEE : 93.15 (+0.32%)
What You Need To Know Ahead of Johnson & Johnson's Earnings Release

Johnson & Johnson is expected to announce its first-quarter results next month, and analysts are projecting a single-digit decline in its EPS.

XLV : 146.81 (-0.62%)
$SPX : 6,582.69 (+0.11%)
JNJ : 243.04 (-0.44%)
2 Safe Dividend Stocks to Buy and Hold Forever

These are two dividend stocks that you can confidently buy, hold, and forget about for decades.

$SPX : 6,582.69 (+0.11%)
PG : 143.12 (-0.67%)
JNJ : 243.04 (-0.44%)
Want Income and Growth? This Simple 3-ETF Portfolio Does Both

In today’s highly volatile market, this simple 3-ETF portfolio combines both steady income and long-term upside.

MO : 65.76 (+0.43%)
AAPL : 255.92 (+0.11%)
AVGO : 314.55 (+0.34%)
CVX : 198.97 (+0.79%)
VZ : 49.40 (+0.02%)
$SPX : 6,582.69 (+0.11%)
JPM : 294.60 (-0.26%)
JNJ : 243.04 (-0.44%)
SCHD : 30.56 (+0.16%)
ABBV : 208.84 (-2.86%)
BMY : 59.60 (-2.45%)
MSFT : 373.46 (+1.11%)
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill

JNJ : 243.04 (-0.44%)
Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

RARITAN, N.J. , March 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing...

JNJ : 243.04 (-0.44%)
Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

97% of patients reported no very bothersome visual disturbances, like halos or glare, with TECNIS PureSee IOL 1 97% of...

JNJ : 243.04 (-0.44%)
Quiet Outperformance From an Overlooked Dividend ETF

DGRO may stand out for investors looking for an ETF focused not only on the highest dividend yields, but on quality dividend payers likely to be stable.

AAPL : 255.92 (+0.11%)
VIG : 216.02 (+0.16%)
XOM : 160.69 (-0.06%)
JNJ : 243.04 (-0.44%)
ABBV : 208.84 (-2.86%)
DGRO : 70.31 (+0.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 251.55
2nd Resistance Point 249.38
1st Resistance Point 246.21
Last Price 243.04
1st Support Level 240.87
2nd Support Level 238.70
3rd Support Level 235.53

See More

52-Week High 251.71
Last Price 243.04
Fibonacci 61.8% 209.61
Fibonacci 50% 196.61
Fibonacci 38.2% 183.60
52-Week Low 141.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.